Short Versus Standard Dental Implants: Clinical and Biomarker Outcomes
15 de septiembre de 2026 actualizado por: Kubra Aral, Inonu University
Comparison of Peri-Implant Tissue Health and Biomarker Outcomes Between Short and Standard Dental Implants: A Prospective Study
This study compares two types of dental implants, short implants (6 millimeters or less in length) and standard implants (longer than 8 millimeters), to evaluate their effect on the health of the gum and bone tissue surrounding the implant.
Approximately 40 patients receiving a total of 80 dental implants will be followed.
Researchers will assess clinical signs of gum health around the implants, measure specific protein levels (biomarkers) in the fluid surrounding the implants associated with gum disease.
The goal of this study is to determine whether implant length affects the risk of inflammation or infection around dental implants, which may help guide treatment decisions in the future.
Descripción general del estudio
Estado
Aún no reclutando
Condiciones
Descripción detallada
This is a prospective study enrolling approximately 40 patients who will receive a total of 80 dental implants, categorized as short (≤6 mm) or standard (>8 mm) in length.
Peri-implant crevicular fluid (PICF) samples will be collected at baseline from all patients.
In patients who develop peri-implant mucositis, an additional PICF sample will be collected at 1 and 3 months.
PICF samples will be analyzed by ELISA for RANKL, OPG, cathepsin-K, and cytokine levels.
Implant diameter and length will be recorded for each patient.
Clinical parameters of peri-implant tissue health will also be assessed at each visit.
The study aims to compare biochemical and clinical outcomes between short and standard implants to determine whether implant length influences peri-implant tissue health.
Tipo de estudio
De observación
Inscripción (Estimado)
40
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Kubra Aral
- Número de teléfono: 05330578801
- Correo electrónico: drkubraaral@gmail.com
Ubicaciones de estudio
-
-
-
Malatya, Turquía (Türkiye)
- Inonu University Faculty of Dentistry
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Sí
Método de muestreo
Muestra no probabilística
Población de estudio
Adult patients presenting to the Department of Periodontology, Faculty of Dentistry, Inonu University, for routine dental check-up, who have at least one short (≤6 mm) and/or standard (>8 mm) dental implant in function for at least 2 years.
Descripción
Inclusion Criteria:
- Systemically healthy adults aged 18-70 years.
- Presence of at least one short (≤6 mm) and/or standard (>8 mm) dental implant in function for at least 2 years.
- Patients presenting to the Department of Periodontology, Faculty of Dentistry, Inonu University, for routine dental examination.
- For the peri-implant health group: absence of clinical signs of inflammation (redness, edema, or suppuration), absence of bleeding on probing (BOP), probing pocket depth (PPD) ≤5 mm, full-mouth BOP <10%, no radiographic evidence of pathological peri-implant bone loss, and no clinical implant mobility.
- For the peri-implant mucositis group: presence of clinical signs of inflammation (redness and/or edema) without suppuration, presence of bleeding on probing (BOP), probing pocket depth (PPD) ≤5 mm, full-mouth BOP >10%, no radiographic evidence of pathological peri-implant bone loss, and no clinical implant mobility.
Exclusion Criteria:
- Age younger than 18 years or older than 70 years.
- Presence of any systemic disease.
- Immune system disorders or use of immunosuppressive medications.
- Requirement for antibiotic prophylaxis before dental procedures.
- Bisphosphonate therapy for osteoporosis.
- Pregnancy or lactation.
- Smoking.
- Alcohol consumption.
- Antibiotic treatment within the previous 6 months.
- Continuous use of systemic medications.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Short implant group
Patients receiving dental implants with a length of 6 mm or less.
Peri-implant crevicular fluid (PICF) samples will be collected to assess RANKL, OPG, and cathepsin-K levels, along with clinical peri-implant tissue health parameters
|
|
Standard Implant Group
Patients receiving dental implants with a length greater than 8 mm.
Peri-implant crevicular fluid (PICF) samples will be collected to assess RANKL, OPG, and cathepsin-K levels, along with clinical peri-implant tissue health parameters.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Peri-Implant Crevicular Fluid RANKL Level
Periodo de tiempo: Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
|
Receptor activator of nuclear factor kappa-B ligand (RANKL) levels in peri-implant crevicular fluid (PICF) will be measured using enzyme-linked immunosorbent assay (ELISA) and compared between short and standard implant groups.
|
Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
|
|
Change in Peri-Implant Crevicular Fluid OPG Level
Periodo de tiempo: Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
|
Osteoprotegerin (OPG) levels in peri-implant crevicular fluid (PICF) will be measured using enzyme-linked immunosorbent assay (ELISA) and compared between short and standard implant groups.
|
Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
|
|
Change in Peri-Implant Crevicular Fluid Cathepsin K Level
Periodo de tiempo: Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
|
Cathepsin K levels in peri-implant crevicular fluid (PICF) will be measured using enzyme-linked immunosorbent assay (ELISA) and compared between short and standard implant groups.
|
Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Peri-Implant Probing Depth
Periodo de tiempo: Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
|
Peri-implant probing depth (PPD) will be measured in millimeters using a periodontal probe at six sites around each implant and compared between short and standard implant groups.
|
Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
|
|
Change in Peri-Implant Bleeding on Probing
Periodo de tiempo: Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
|
Bleeding on probing (BOP) will be assessed following gentle probing around each implant and recorded as the percentage of sites exhibiting bleeding.
|
Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
|
|
Change in Peri-Implant Plaque Index
Periodo de tiempo: Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
|
Peri-implant plaque accumulation will be evaluated using the Plaque Index (PI) and compared between short and standard implant groups.
|
Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
|
|
Change in Gingival Index
Periodo de tiempo: Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
|
Peri-implant soft tissue inflammation will be evaluated using the Gingival Index (mGI) and compared between short and standard implant groups.
|
Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Berglundh T, Armitage G, Araujo MG, Avila-Ortiz G, Blanco J, Camargo PM, Chen S, Cochran D, Derks J, Figuero E, Hammerle CHF, Heitz-Mayfield LJA, Huynh-Ba G, Iacono V, Koo KT, Lambert F, McCauley L, Quirynen M, Renvert S, Salvi GE, Schwarz F, Tarnow D, Tomasi C, Wang HL, Zitzmann N. Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol. 2018 Jun;45 Suppl 20:S286-S291. doi: 10.1111/jcpe.12957.
- Guarnieri R, Di Nardo D, Gaimari G, Miccoli G, Testarelli L. Short vs. Standard Laser-Microgrooved Implants Supporting Single and Splinted Crowns: A Prospective Study with 3 Years Follow-Up. J Prosthodont. 2019 Feb;28(2):e771-e779. doi: 10.1111/jopr.12959. Epub 2018 Aug 31.
- Karci BL, Oncu E. Comparison of Osteoimmunological and Microbiological Parameters of Extra Short and Longer Implants Loaded in the Posterior Mandible: A Split Mouth Randomized Clinical Study. Acta Stomatol Croat. 2021 Sep;55(3):238-247. doi: 10.15644/asc55/3/1.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Estimado)
20 de septiembre de 2026
Finalización primaria (Estimado)
30 de diciembre de 2026
Finalización del estudio (Estimado)
30 de diciembre de 2026
Fechas de registro del estudio
Enviado por primera vez
10 de septiembre de 2026
Primero enviado que cumplió con los criterios de control de calidad
15 de septiembre de 2026
Publicado por primera vez (Actual)
18 de septiembre de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
18 de septiembre de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
15 de septiembre de 2026
Última verificación
1 de septiembre de 2026
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- 2026/11007
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
SÍ
Descripción del plan IPD
De-identified individual participant data will be shared, including participant age, sex, and clinical periodontal parameters (plaque index, gingival index, probing depth, clinical attachment level, bleeding on probing).
Participants will be identified only by coded/numbered case report forms; no names, gender identity beyond biological sex, or other identifying information will be shared.
Marco de tiempo para compartir IPD
Beginning 6 months and ending 24 months following article publication
Criterios de acceso compartido de IPD
Data will be made available to researchers who provide a methodologically sound proposal, subject to approval by the corresponding author, for the purpose of achieving the aims outlined in the approved proposal.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .